Biomarker & Intervention Discovery

Long COVID / Post-Acute Sequelae of COVID-19 (PASC)

This page lists 7 druggable gene targets, 27 approved or trial-tested drug candidates and 15 recent clinical trials for Long COVID / Post-Acute Sequelae of COVID-19 (PASC), with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Spontaneous remissionSpontaneous resolution at 12 months: ~50-70% of patients; persistent symptoms at 2 years in 30-50%; severely…
Best-intervention remissionNo approved pharmacotherapy; Paxlovid (nirmatrelvir/ritonavir) — PANORAMIC trial showed no reduction in Long COVID…
Gap sizeVery large — no proven pharmacotherapy; enormous research investment but no approved treatment as of mid-2026
Primary barrierbiological (mechanism not fully understood) + practice (no evidence-based protocol)
Full remission profile →
Research Tracker Chronic Disease Interventions Long COVID / Post-Acute COVID Sequelae (PACVS)

Remission & chronicity

Spontaneous remission
Spontaneous resolution at 12 months: ~50-70% of patients; persistent symptoms at 2 years in 30-50%; severely debilitating long COVID in 10-15% at 1 year without intervention
Best-intervention remission
No approved pharmacotherapy; Paxlovid (nirmatrelvir/ritonavir) — PANORAMIC trial showed no reduction in Long COVID risk at 6 months if started in acute phase; BC007 (autoantibody neutraliser) — Phase 2 signal; low-dose naltrexone — observational data positive; antihistamine combination (famotidine + cetirizine) — anecdotal
Gap size
Very large — no proven pharmacotherapy; enormous research investment but no approved treatment as of mid-2026
Primary barrier
biological (mechanism not fully understood) + practice (no evidence-based protocol)
Long COVID is a heterogeneous syndrome with multiple proposed mechanisms (viral persistence, autoimmunity, microclotting, dysautonomia, mitochondrial dysfunction); no single treatment works for all patients; fragmented care with poor coordination; many clinicians still do not acknowledge Long COVID as a diagnosis

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

ACE2 147IFNL3 25IL6 181NOS3 0TLR3 18TNF 287TRPV1 187

ACE2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
MLN-4760 ↓ inhibits Mechanistic DGIdb
ABZ-SER-PRO-TYR(NO2)-OH ? unclear Mechanistic DGIdb
BCY15291 ↓ inhibits Mechanistic DGIdb
ALUNACEDASE ALFA ? unclear Mechanistic DGIdb
LISINOPRIL ANHYDROUS ? unclear Mechanistic DGIdb
XNT [PMID: 18391097] ↑ activates Mechanistic DGIdb
ORE-1001 ? unclear Mechanistic 0.44 nM (IC50) DGIdb
COMPOUND 28 [PMID: 18324760] ↓ inhibits Mechanistic DGIdb
DX600 ↓ inhibits Mechanistic DGIdb
CPS4 ? unclear Mechanistic DGIdb
CHEMBL252391 ↓ inhibits Mechanistic 1.5 nM (Ki) ChEMBL
CHEMBL252009 ↓ inhibits Mechanistic 84.0 nM (Ki) ChEMBL
CHEMBL251809 ↓ inhibits Mechanistic 35.0 nM (Ki) ChEMBL
CHEMBL251808 ↓ inhibits Mechanistic 0.85 nM (Ki) ChEMBL
CHEMBL398771 ↓ inhibits Mechanistic 2.0 nM (Ki) ChEMBL
CHEMBL254911 ↓ inhibits Mechanistic 2.5 nM (Ki) ChEMBL
CHEMBL254703 ↓ inhibits Mechanistic 2.7 nM (Ki) ChEMBL
CHEMBL254495 ↓ inhibits Mechanistic 2.4 nM (Ki) ChEMBL
CHEMBL254493 ↓ inhibits Mechanistic 6.0 nM (Ki) ChEMBL
CHEMBL254282 ↓ inhibits Mechanistic 2.2 nM (Ki) ChEMBL
CHEMBL252003 ↓ inhibits Mechanistic 5.8 nM (Ki) ChEMBL
CHEMBL251804 ↓ inhibits Mechanistic 0.9 nM (Ki) ChEMBL
CHEMBL401397 ↓ inhibits Mechanistic 2.2 nM (Ki) ChEMBL
CHEMBL398545 ↓ inhibits Mechanistic 37.0 nM (Ki) ChEMBL
CHEMBL253428 ↓ inhibits Mechanistic 2.4 nM (Ki) ChEMBL
CHEMBL400527 ↓ inhibits Mechanistic 2.2 nM (Ki) ChEMBL
CHEMBL253224 ↓ inhibits Mechanistic 1.3 nM (Ki) ChEMBL
CHEMBL400526 ↓ inhibits Mechanistic 1.5 nM (Ki) ChEMBL
CHEMBL254900 ↓ inhibits Mechanistic 14.0 nM (Ki) ChEMBL
CHEMBL401086 ↓ inhibits Mechanistic 90.0 nM (Ki) ChEMBL
CHEMBL252417 ↓ inhibits Mechanistic 62000.0 nM (IC50) ChEMBL
CHEMBL398940 ↓ inhibits Mechanistic 57000.0 nM (IC50) ChEMBL
CHEMBL436639 ↓ inhibits Mechanistic 10.0 nM (IC50) ChEMBL
CHEMBL350414 ↓ inhibits Mechanistic 86.0 nM (Ki) ChEMBL
CHEMBL402987 ↓ inhibits Mechanistic 860.0 nM (Ki) ChEMBL
CHEMBL272925 ↓ inhibits Mechanistic 550.0 nM (Ki) ChEMBL
CHEMBL271224 ↓ inhibits Mechanistic 420.0 nM (Ki) ChEMBL
CHEMBL271223 ↓ inhibits Mechanistic 7.1 nM (Ki) ChEMBL
CHEMBL271225 ↓ inhibits Mechanistic 1.4 nM (Ki) ChEMBL
CHEMBL437595 ↓ inhibits Mechanistic 84.0 nM (Ki) ChEMBL

Showing top 40 of 147 agents ranked by evidence tier.

IFNL3

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
GRAZOPREVIR ? unclear Mechanistic DGIdb
TELAPREVIR ? unclear Mechanistic DGIdb
RITONAVIR ? unclear Mechanistic DGIdb
ASUNAPREVIR ? unclear Mechanistic DGIdb
FALDAPREVIR ? unclear Mechanistic DGIdb
BOCEPREVIR ? unclear Mechanistic DGIdb
LEDIPASVIR ? unclear Mechanistic DGIdb
INTERFERON ALFA-N1 ? unclear Mechanistic DGIdb
OMBITASVIR/PARITAPREVIR/RITONAVIR ? unclear Mechanistic DGIdb
OMBITASVIR ? unclear Mechanistic DGIdb
ATORVASTATIN ? unclear Mechanistic DGIdb
ELBASVIR ? unclear Mechanistic DGIdb
SOFOSBUVIR ? unclear Mechanistic DGIdb
SOFOSBUVIR/VELPATASVIR ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2B ? unclear Mechanistic DGIdb
DELEOBUVIR ? unclear Mechanistic DGIdb
VOXILAPREVIR ? unclear Mechanistic DGIdb
DASABUVIR ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2A ? unclear Mechanistic DGIdb
SOFOSBUVIR / VELPATASVIR / VOXILAPREVIR ? unclear Mechanistic DGIdb
ELBASVIR/GRAZOPREVIR ? unclear Mechanistic DGIdb
DACLATASVIR ? unclear Mechanistic DGIdb
PARITAPREVIR ? unclear Mechanistic DGIdb
SIMEPREVIR ? unclear Mechanistic DGIdb
VELPATASVIR ? unclear Mechanistic DGIdb

IL6

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CLAZAKIZUMAB ↓ inhibits Mechanistic DGIdb
MIDOSTAURIN ? unclear Mechanistic DGIdb
ECHINACEA EXTRACT ? unclear Mechanistic DGIdb
NELFINAVIR ? unclear Mechanistic DGIdb
SELECTIVE ESTROGEN RECEPTOR MODULATOR ? unclear Mechanistic DGIdb
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic DGIdb
OLOKIZUMAB ? unclear Mechanistic DGIdb
IBUDILAST ? unclear Mechanistic DGIdb
VITAMIN A PALMITATE ? unclear Mechanistic DGIdb
IFOSFAMIDE ? unclear Mechanistic DGIdb
SITAGLIPTIN ? unclear Mechanistic DGIdb
METRONIDAZOLE ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2A ? unclear Mechanistic DGIdb
PACIBEKITUG ↓ inhibits Mechanistic DGIdb
PEGINTERFERON ALFA-2B ? unclear Mechanistic DGIdb
SIRUKUMAB ↓ inhibits Mechanistic DGIdb
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic DGIdb
SAFINGOL ? unclear Mechanistic DGIdb
ENZYME INHIBITOR ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
GALLIUM NITRATE ? unclear Mechanistic DGIdb
RITUXIMAB ? unclear Mechanistic DGIdb
INFLIXIMAB ? unclear Mechanistic DGIdb
C326 ? unclear Mechanistic DGIdb
GEMFIBROZIL ? unclear Mechanistic DGIdb
ZILTIVEKIMAB ? unclear Mechanistic DGIdb
INSULIN, REGULAR, HUMAN ? unclear Mechanistic DGIdb
OSIMERTINIB ? unclear Mechanistic DGIdb
BINETRAKIN ? unclear Mechanistic DGIdb
ALOGLIPTIN ? unclear Mechanistic DGIdb
TENELIGLIPTIN ? unclear Mechanistic DGIdb
CHINESE HERBS ? unclear Mechanistic DGIdb
TOCILIZUMAB ? unclear Mechanistic DGIdb
LINAGLIPTIN ? unclear Mechanistic DGIdb
DOCETAXEL ANHYDROUS ? unclear Mechanistic DGIdb
VILDAGLIPTIN ? unclear Mechanistic DGIdb
LINEZOLID ? unclear Mechanistic DGIdb
SELENIUM ? unclear Mechanistic DGIdb
SAQUINAVIR ? unclear Mechanistic DGIdb
PAREGORIC ? unclear Mechanistic DGIdb

Showing top 40 of 181 agents ranked by evidence tier.

NOS3

UniProt Ensembl DGIdb Open Targets

Pipeline results not yet available for this target. Run the pipeline to populate.

TLR3

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
BEVASIRANIB SODIUM ↑ activates Mechanistic DGIdb
POLY ICLC ? unclear Mechanistic DGIdb
RINTATOLIMOD ? unclear Mechanistic DGIdb
BINETRAKIN ? unclear Mechanistic DGIdb
MEASLES VACCINE ? unclear Mechanistic DGIdb
ASPIRIN ? unclear Mechanistic DGIdb
HYDROXYCHLOROQUINE ? unclear Mechanistic DGIdb
BEVASIRANIB ↑ activates Mechanistic DGIdb
RECOMBINANT INTERLEUKIN-13 ? unclear Mechanistic DGIdb
POLY(I:C) ↑ activates Mechanistic DGIdb
CHEMBL4064228 ↑ activates Mechanistic 42500.0 nM (EC50) ChEMBL
CHEMBL4074408 ↑ activates Mechanistic 4800.0 nM (EC50) ChEMBL
CHEMBL4105063 ↑ activates Mechanistic 22300.0 nM (EC50) ChEMBL
CHEMBL4636498 ↓ inhibits Mechanistic 5440.0 nM (IC50) ChEMBL
CHEMBL4647818 ↓ inhibits Mechanistic 2160.0 nM (IC50) ChEMBL
CHEMBL4795714 ↓ inhibits Mechanistic 2400.0 nM (IC50) ChEMBL
CHEMBL19954 ↓ inhibits Mechanistic 110.0 nM (IC50) ChEMBL
CHEMBL4303728 ↓ inhibits Mechanistic 3440.0 nM (IC50) ChEMBL

TNF

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DICLOFENAC SODIUM ? unclear Mechanistic DGIdb
RDP58 ? unclear Mechanistic DGIdb
METHYLENE BLUE ? unclear Mechanistic DGIdb
ORTATAXEL ? unclear Mechanistic DGIdb
CERTOLIZUMAB PEGOL ↓ inhibits Mechanistic DGIdb
OZORALIZUMAB ↓ inhibits Mechanistic DGIdb
THALIDOMIDE ? unclear Mechanistic DGIdb
HUANG LIAN ? unclear Mechanistic DGIdb
GOLIMUMAB ↓ inhibits Mechanistic DGIdb
CYCLOSPORINE ? unclear Mechanistic DGIdb
DOCETAXEL ANHYDROUS ? unclear Mechanistic DGIdb
HALOFUGINONE ? unclear Mechanistic DGIdb
ETANERCEPT ↓ inhibits Mechanistic DGIdb
ISIS 104838 ? unclear Mechanistic DGIdb
GEMCITABINE ? unclear Mechanistic DGIdb
INDOMETHACIN ? unclear Mechanistic DGIdb
INSULIN, REGULAR, HUMAN ? unclear Mechanistic DGIdb
DIDANOSINE ? unclear Mechanistic DGIdb
5,7-DIHYDROXY-4-METHYLCOUMARIN ? unclear Mechanistic DGIdb
SOBLIDOTIN ? unclear Mechanistic DGIdb
STAVUDINE ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
MEROPENEM ANHYDROUS ? unclear Mechanistic DGIdb
AMPHOTERICIN B LIPOSOMAL ? unclear Mechanistic DGIdb
MIDAZOLAM HYDROCHLORIDE ? unclear Mechanistic DGIdb
RIFAMPIN ? unclear Mechanistic DGIdb
AVX-470 ? unclear Mechanistic DGIdb
KETOROLAC TROMETHAMINE ? unclear Mechanistic DGIdb
PRAZOSIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
RISPERIDONE ? unclear Mechanistic DGIdb
BENZO[E]PYRENE ? unclear Mechanistic DGIdb
ETHAMBUTOL HYDROCHLORIDE ? unclear Mechanistic DGIdb
REMTOLUMAB ↓ inhibits Mechanistic DGIdb
SPIRONOLACTONE ? unclear Mechanistic DGIdb
OMEPRAZOLE ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
MITOMYCIN C ANALOG KW-2149 ? unclear Mechanistic DGIdb
NAFAMOSTAT ? unclear Mechanistic DGIdb
ABBV-3373 ~ modulates Mechanistic DGIdb
BACILLUS CALMETTE-GUERIN ANTIGEN ? unclear Mechanistic DGIdb

Showing top 40 of 287 agents ranked by evidence tier.

TRPV1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
RHTX ↑ activates Mechanistic DGIdb
ABT-102 ↓ inhibits Mechanistic DGIdb
ASIVATREP ↓ inhibits Mechanistic DGIdb
BCTC ↓ inhibits Mechanistic DGIdb
MAVATREP ↓ inhibits Mechanistic DGIdb
POLYGODIAL ? unclear Mechanistic DGIdb
ALLICIN ↓ inhibits Mechanistic DGIdb
JTS-653 ↓ inhibits Mechanistic DGIdb
SB452533 ↓ inhibits Mechanistic DGIdb
MR-1817 ↓ inhibits Mechanistic DGIdb
GRC-6211 ↓ inhibits Mechanistic DGIdb
ACETAMINOPHEN ↑ activates Mechanistic DGIdb
DWP05195 ↓ inhibits Mechanistic DGIdb
STREPTOZOCIN ? unclear Mechanistic DGIdb
CAPSAICIN ↑ activates Mechanistic 19.95 nM (EC50) DGIdb
AMG517 ↓ inhibits Mechanistic DGIdb
5S-HETE ↑ activates Mechanistic DGIdb
BENZYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
MASOPROCOL ? unclear Mechanistic DGIdb
[3H]RESINIFERATOXIN ↑ activates Mechanistic DGIdb
[3H]A778317 ↓ inhibits Mechanistic DGIdb
CAPSAZEPINE ↓ inhibits Mechanistic 120.0 nM (Ki) DGIdb
NABIXIMOLS ? unclear Mechanistic DGIdb
H+ ↑ activates Mechanistic DGIdb
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic DGIdb
NADA ↓ inhibits Mechanistic DGIdb
ZUCAPSAICIN ↑ activates Mechanistic DGIdb
SB366791 ↓ inhibits Mechanistic DGIdb
GRC-15300 ? unclear Mechanistic DGIdb
MRS-1477 ~ modulates Mechanistic DGIdb
ANANDAMIDE ↑ activates Mechanistic DGIdb
JNJ17203212 ↓ inhibits Mechanistic DGIdb
LEVODOPA ? unclear Mechanistic DGIdb
INDOMETHACIN ? unclear Mechanistic DGIdb
AZD1386 ↓ inhibits Mechanistic DGIdb
CAMPHOR OIL ↑ activates Mechanistic DGIdb
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
VOACANGINE ? unclear Mechanistic DGIdb
FERRUGINENE B ? unclear Mechanistic DGIdb
PHENYLACETYLRINVANIL ↑ activates Mechanistic DGIdb

Showing top 40 of 187 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Long COVID / Post-Acute Sequelae of COVID-19 (PASC): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

RECOVER-AUTONOMIC Platform Protocol Completed
NCT06305780 Phase: 2 Started: 2024-03-11

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm...

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG) Completed
NCT06305793 Phase: 2 Started: 2024-05-08

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm...

RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD) Completed
NCT06404112 Phase: 2 Started: 2024-07-31

The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. ...

RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia) Completed
NCT06404099 Phase: 2 Started: 2024-08-12

The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. ...

Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 Recruiting
NCT06960928 Phase: 3 Started: 2025-04-18

The study is conducted in New York, New York at The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai. This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled clinical trial of sirolimus (also known as rapamycin) in adults with Long COVID. There are 2 ar...

RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms Completed
NCT05965726 Phase: 2 Started: 2023-07-26

This is an appendix of master protocol (NCT05595369) designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This sub-study is a prospective, mul...

RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) Completed
NCT06305806 Phase: 2 Started: 2024-03-11

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm...

Amantadine Therapy for Cognitive Impairment in Long COVID Completed
NCT06055244 Phase: 2 Started: 2023-12-07

This study will look at the effects of amantadine on cognitive function in persons with Long COVID. It will also collect specimens to study possible causes of cognitive symptoms in Long COVID, and whether any lab tests can predict who will respond better to amantadine.

RECOVER-SLEEP: Platform Protocol Completed
NCT06404086 Phase: 2 Started: 2024-07-31

The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. ...

RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms Completed
NCT05595369 Phase: 2 Started: 2023-07-26

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm...

Paxlovid for Treatment of Long Covid Completed
NCT05576662 Phase: 2 Started: 2022-11-08

The purpose of this study is to compare whether being treated with nirmatrelvir plus ritonavir for 15 days works better than being treated with placebo plus ritonavir to reduce severe symptoms of Long Covid. Participants will have 5 planned visits to the study clinic over 15 weeks and will take the ...

Synbiotic Therapy for NP-PASC Completed
NCT06620406 Phase: N/A Started: 2024-12-09

Gut microbiome dysbiosis has been noted in patients with Post-acute sequelae (PASC) of Severe Acute Respiratory Syndrome-CoronaVirus -2 (SARS-CoV-2). A study performed at Columbia found that plasma levels of the short chain fatty acid (SCFA), butyric acid, remained lower in people with Neuropsychiat...

Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID Completed
NCT05638620 Phase: 1 Started: 2023-01-03

The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2 Completed
NCT06316843 Phase: 2 Started: 2023-10-15

To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19.

Vortioxetine for Post-COVID-19 Condition Completed
NCT05047952 Phase: 2 Started: 2021-09-16

A randomized, double-blinded, placebo-controlled trial will be conducted to evaluate vortioxetine, an antidepressant with established pro-cognitive properties, for the treatment of cognitive deficits which develop during or after an infection consistent with COVID-19, continue for 2+ months, and are...

Agents Found By Disease-Level Search

Searched directly from “Long COVID / Post-Acute COVID Sequelae (PACVS)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 7-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

27 agents shown (approved or with trial evidence) — 27 not found by the gene-target search above.

ImmunoadsorptionNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT05841498 NCT05710770

ModafinilNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06404086

SolriamfetolNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06404086

MelatoninNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT06404086

WATER+CTNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06142253

Inspiratory muscle trainerNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04919031

SpirometryNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05077982

6-minute walkNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05077982

Vitamin K2 (MK-7)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05356936

Vitamin D3NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05356936

N-Tidal C handsetNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04939558

Complementary self-help strategies in addition to treatment as usualNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05798221

Physical FatigueNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07278388

ActiveNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06063031

Hyperbaric Oxygen therapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06452095

Levels of inflammatory cytokine ( IL-6) in post-COVID-19 POTS and controlsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05421208

Levels of inflammatory cytokine ( IL-6) in controlsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05421208

SonlicromanolNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07298005

Treatment as usualNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05793736

Computed Tomography of the ChestNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05866952

DAOIBNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05764538

COVAXINNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05142319

NuvaxovidNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05142319

Probiotic AgentNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06643299

ubiquinol (reduced coenzyme Q10)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05178225

2x14 ml of peripheral blood collected in a tube with anticoagulantNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05178225

Institutional standard treatment for xerostomia and Long CovidNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05760092

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.